Zepzelca (Lurbinectedin) is an alkylating drug used for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
Dosage: The recommended dosage of Lurbinectedin is 3.2 mg/m2 by intravenous infusion over 60 minutes every 21 days until the disease is progressive or any unacceptable toxicity occurs. Treatment with Lurbinectedin should be initiated only if absolute neutrophil count (ANC) is at least 1,500 cells/mm3 and platelet count is at least 100,000/mm3.
Side Effects: The most commonly reported zepzelca side effects (≥20%) include:
- Increased creatinine
- Increased alanine aminotransferase
- Increased glucose
- Decreased appetite
- Musculoskeletal pain
- Decreased albumin
- Decreased sodium
- Decreased magnesium
- Increased aspartate aminotransferase
Warnings and Precautions:
- Monitor patients with lurbinectedin injection for blood counts including neutrophil count and platelet count prior to each administration.
- Monitor patients for liver function tests, before initiating Lurbinectedin, periodically during treatment, and as clinically indicated.
- Patients receiving treatment with zepzelca injection should immediately contact their health specialist for fever, other signs of infection, bleeding, unusual bruising, tiredness or pallor.
- Findings indicate that zepzelca uses can be responsible for causing fetal harm during pregnancy. Women must inform their health specialist of a known or suspected pregnancy.
- Respective women should avoid breastfeeding while receiving zepzelca dose and for at least 2 weeks after the final dose.